The abstract is read at the publisher; the summary is JClub's.
The 2025 GLADEL-PANLAR guidelines update organ-based systemic lupus erythematosus treatment algorithms, integrating newly approved therapies and randomized trial evidence to support earlier biologic use.
- Why it matters: Rapid lupus treatment advances—especially for lupus nephritis and musculoskeletal and cutaneous disease—create a need for updated, evidence-based guidance tailored to Latin America’s access and resource constraints.
- What they did: The Latin American Group for the Study of Lupus-Pan-American League of Associations for Rheumatology revises the 2018 recommendations with newly approved therapies and randomized controlled trial data, plus overarching good-practice statements.
- The result: The recommendations promote treat-to-target care aiming for remission or low disease activity, with sustained remission as the optimal long-term outcome, while encouraging individualized optimization and strategies to minimize glucocorticoid exposure.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.